Pallas Capital Advisors LLC Takes Position in Natera, Inc. (NASDAQ:NTRA)

Pallas Capital Advisors LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 4,209 shares of the medical research company’s stock, valued at approximately $426,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after purchasing an additional 60,127 shares during the last quarter. Thematics Asset Management increased its stake in Natera by 3.1% in the 4th quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock valued at $5,652,000 after buying an additional 2,738 shares during the period. Crestline Management LP raised its position in Natera by 16.0% during the 4th quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after buying an additional 8,997 shares during the last quarter. Hamilton Lane Advisors LLC acquired a new stake in shares of Natera in the 4th quarter worth $616,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after acquiring an additional 9,781 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In other Natera news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now directly owns 287,441 shares in the company, valued at approximately $34,783,235.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Natera news, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the transaction, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 5,583 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the sale, the chief executive officer now owns 200,710 shares of the company’s stock, valued at $23,866,426.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 101,891 shares of company stock worth $11,244,549. Corporate insiders own 7.60% of the company’s stock.

Natera Price Performance

Shares of Natera stock traded up $1.44 during trading on Wednesday, hitting $119.89. 131,535 shares of the company were exchanged, compared to its average volume of 1,387,941. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $124.72. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. The firm has a 50 day moving average price of $109.34 and a 200 day moving average price of $98.03. The stock has a market capitalization of $14.72 billion, a price-to-earnings ratio of -38.43 and a beta of 1.48.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.97) earnings per share. On average, equities analysts expect that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several analyst reports. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Tuesday. UBS Group reduced their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. Robert W. Baird upped their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Jefferies Financial Group initiated coverage on Natera in a report on Monday, June 3rd. They issued a “buy” rating and a $142.00 target price for the company. Finally, BTIG Research boosted their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.